Richardson PG - Search Results

1

Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.

Potts BC, Albitar MX, Anderson KC, Baritaki S, Berkers C, Bonavida B, Chandra J, Chauhan D, Cusack JC Jr, Fenical W, Ghobrial IM, Groll M, Jensen PR, Lam KS, Lloyd GK, McBride W, McConkey DJ, Miller CP, Neuteboom ST, Oki Y, Ovaa H, Pajonk F, Richardson PG, Roccaro AM, Sloss CM, Spear MA, Valashi E, Younes A, Palladino MA. Potts BC, et al. Among authors: richardson pg. Curr Cancer Drug Targets. 2011 Mar;11(3):254-84. doi: 10.2174/156800911794519716. Curr Cancer Drug Targets. 2011. PMID: 21247382 Free PMC article. Review.

2

Proteasome inhibition as a new therapeutic principle in hematological malignancies.

Mitsiades CS, Mitsiades N, Hideshima T, Richardson PG, Anderson KC. Mitsiades CS, et al. Among authors: richardson pg. Curr Drug Targets. 2006 Oct;7(10):1341-7. doi: 10.2174/138945006778559247. Curr Drug Targets. 2006. PMID: 17073596 Review.

3

Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma.

Chauhan D, Singh AV, Ciccarelli B, Richardson PG, Palladino MA, Anderson KC. Chauhan D, et al. Among authors: richardson pg. Blood. 2010 Jan 28;115(4):834-45. doi: 10.1182/blood-2009-03-213009. Epub 2009 Nov 13. Blood. 2010. PMID: 19965674 Free PMC article.

4

Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.

Levin N, Spencer A, Harrison SJ, Chauhan D, Burrows FJ, Anderson KC, Reich SD, Richardson PG, Trikha M. Levin N, et al. Among authors: richardson pg. Br J Haematol. 2016 Sep;174(5):711-20. doi: 10.1111/bjh.14113. Epub 2016 May 9. Br J Haematol. 2016. PMID: 27161872 Free PMC article. Clinical Trial.

5

Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers.

Richardson PG, Hideshima T, Anderson KC. Richardson PG, et al. Cancer Control. 2003 Sep-Oct;10(5):361-9. doi: 10.1177/107327480301000502. Cancer Control. 2003. PMID: 14581890 Free article. Review.

6

Proteasome inhibition in the treatment of cancer.

Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Richardson PG, et al. Cell Cycle. 2005 Feb;4(2):290-6. Epub 2005 Feb 3. Cell Cycle. 2005. PMID: 15655370 Review.

7

Bortezomib: a novel therapy approved for multiple myeloma.

Richardson PG, Anderson KC. Richardson PG, et al. Clin Adv Hematol Oncol. 2003 Oct;1(10):596-600. Clin Adv Hematol Oncol. 2003. PMID: 16258456 Review.

8

Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma.

Hideshima T, Richardson PG, Anderson KC. Hideshima T, et al. Among authors: richardson pg. Mol Cancer Ther. 2011 Nov;10(11):2034-42. doi: 10.1158/1535-7163.MCT-11-0433. Mol Cancer Ther. 2011. PMID: 22072815 Free PMC article. Review.

9

The proteasome and proteasome inhibitors in multiple myeloma.

Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Anderson KC, Richardson PG. Gandolfi S, et al. Among authors: richardson pg. Cancer Metastasis Rev. 2017 Dec;36(4):561-584. doi: 10.1007/s10555-017-9707-8. Cancer Metastasis Rev. 2017. PMID: 29196868 Review.

10

Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia.

Laubach JP, Mitsiades CS, Roccaro AM, Ghobrial IM, Anderson KC, Richardson PG. Laubach JP, et al. Among authors: richardson pg. Leuk Lymphoma. 2009 May;50(5):694-702. doi: 10.1080/10428190902866732. Leuk Lymphoma. 2009. PMID: 19452315 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

571 results

Search Page